Bicara Therapeutics GAAP EPS of -$1.04 misses by $0.22
- Bicara Therapeutics press release (BCAX): Q3 GAAP EPS of -$1.04 misses by $0.22.
- Cash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Bicara had cash, cash equivalents and marketable securities of $442.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.